Life4me+ news story
The PURPOSE 5 study, presented at HIV Glasgow 2026, found substantially higher persistence with twice-yearly lenacapavir injections than with daily oral PrEP. But questions about the limited representation of women highlighted a broader challenge: scientific innovation alone cannot overcome inequalities in access to HIV prevention.
Read the full news story here.
View all Life4me+ reports from HIV Glasgow 2026
Source : Life4me+
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.